** Shares of weight-loss drug developer of Veru VERU.O rise 46% to 74 cents premarket
** VERU says combination of its experimental drug, enobosarm, and semaglutide resulted in fewer gastrointestinal side effects such as diarrhea and nausea in mid-stage trial, compared with semaglutide alone
** Combo drug met main goal of mid-stage trial earlier this year
** Patients taking enobosarm 3mg with semaglutide saw 99% loss of fat while preserving lean muscle mass, co says
** VERU has requested meeting with U.S. FDA to discuss next steps for enobosarm, including potential late-stage trial
** As of last close, stock down 21.8% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。